Edward Schaeffer, PhD
Urology · Chicago, ILNPI 1821134883
Payments from drug & device makers
What this record shows
This record is dominated by other: $125,506 of the $208,690 with a category attached, or 60.1%. Boston Scientific accounts for 60.2% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $127,726, more than ten times the $2,357 reported in 2019. Among urology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 53 payments — averaging $3937.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$126K
- Pfizer$25K
- Progenics Pharmaceuticals, Inc.$22K
- Astellas Pharma Global Development$21K
- Astellas Pharma US Inc$9K
- AbbVie$3K
- plus $4K from 5 others
Across 7 payments — averaging $814.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Progenics Pharmaceuticals, Inc.$5K
- Astellas Pharma Global Development$1K
What the payments were for
- Consulting fees$57,86528%
- Speaking & faculty fees$20,64310%
- Travel & lodging$2,9331%
- Food & beverage$1,7431%
- Other$125,50660%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 2 | $125,626 |
| Pfizer | 26 | $25,291 |
| Progenics Pharmaceuticals, Inc. | 6 | $21,945 |
| Astellas Pharma Global Development | 2 | $21,060 |
| Astellas Pharma US Inc | 7 | $8,525 |
| AbbVie | 1 | $2,500 |
| Janssen Scientific Affairs, LLC | 3 | $2,070 |
| Myriad Genetic Laboratories, Inc. | 1 | $1,100 |
| Sanofi | 2 | $287 |
| AstraZeneca | 1 | $238 |
| Travere Therapeutics, Inc. | 2 | $49 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$125,506
- XTANDI$41,615
- PYLARIFY$21,945
- TALZENNA$13,563
- Lupron Depot$2,500
- Erleada$2,020
- Prolaris$1,100
- ORGOVYX$1,001
- NO PRODUCT DISCUSSED$287
- GENERAL BPH$120
How this compares
$208,690 in reported general payments places this provider in the 95th percentile of 550 urology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 11 | $28,583 |
| Gentamicin Sulfate | 146 | $2,018 |
| Tamsulosin Hcl | 69 | $1,345 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 28 | $512 |
| Finasteride | 21 | $322 |
| Sodium Chloride0.9 % Sodium Chloride | 18 | $85 |
Paid to pharmacies, not to this prescriber.
Other urology in Chicago
- Gary SteinbergChicago$529K
- Simone CrivellaroChicago$526K
- Brian HelfandChicago$517K
- Ashley RossChicago$404K
- Amy KrambeckChicago$356K
- Kevin ZornChicago$274K
- Joshua MeeksChicago$248K
- Paul YonoverChicago$179K
- Omer RaheemChicago$148K
- Piyush AgarwalChicago$146K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.